Eli Lilly and Company Dossier

In the second quarter of FY2025, Eli Lilly and Company generated revenue of $15.56 billion and operating income of $6.87 billion, capitalizing on the robust commercial uptake of its metabolic medicines. The Indianapolis-based pharmaceutical manufacturer achieved these results primarily through the substantial market performance of its key incretin-based therapies, Mounjaro and Zepbound.

Financial Highlights

* Second-quarter FY2025 revenue: $15.56 billion

* Second-quarter FY2025 operating income: $6.87 billion

* Second-quarter FY2025 net income: $5.66 billion

* Second-quarter FY2025 diluted earnings per share: $6.29

* Mounjaro second-quarter revenue: $5.20 billion

* Zepbound second-quarter revenue: $3.38 billion

* Updated full-year FY2025 revenue guidance: $60.0 billion to $62.0 billion

* Updated full-year FY2025 reported EPS guidance: $20.85 to $21.10

Eli Lilly and Company continues to consolidate its market leadership in the metabolic disease sector, with Mounjaro and Zepbound collectively contributing over half of the company's quarterly revenue. To support this trajectory and address supply constraints, the enterprise... Sign in / Sign up to learn more about Eli Lilly and Company

Continue your research by chatting with our AI financial analyst about Eli Lilly and Company. Ask follow-up questions, request specific analysis, or explore investment scenarios. All insights are grounded in verified financial data and SEC filings.

Start your analysis with these investor-focused questions:

• Given that Mounjaro and Zepbound now account for over half of total revenue, what are the primary risks to Eli Lilly and Company achieving its raised FY2025 revenue guidance of $60-$62 billion, and how are strategic investments in manufacturing intended to mitigate these risks?
• How does Eli Lilly and Company's R&D strategy, including recent pipeline adjustments and acquisitions like SiteOne Therapeutics, position it against key competitor Novo Nordisk to maintain long-term leadership in the cardiometabolic market?
• Considering the ongoing insulin pricing litigation and potential for future regulatory pressure on GLP-1 drug prices, how could these factors impact Eli Lilly and Company's operating margins and its ability to fund its aggressive capital allocation strategy?
• With significant capital investments planned for manufacturing expansion, how should an analyst assess the potential impact on Eli Lilly and Company's free cash flow and return on invested capital over the next several years?
• Eli Lilly and Company's valuation reflects high growth expectations. What specific clinical trial milestones or market developments would be most critical for justifying its current valuation, and conversely, what competitive or regulatory events pose the greatest threat?